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Results: Only 1 of 11,836 (0.01%) SA strains exhibited non-
susceptibility to daptomycin (MIC, 2mg/L), and resistance to
oxacillin or other antimicrobials did not adversely inﬂuence
daptomycin activity. Daptomycin was active against ente-
rococci (100.0% susceptible), including strains resistant to
vancomycin. Vancomycin-resistant E. faecium increased in
Europe from 12.0% in 2004 to 25.8% in 2007 and varied signiﬁ-
cantly by country. Only 72.1% of E. faecium were susceptible
to quinupristin/dalfopristin. All VGS strains resistant to
penicillin and/or clindamycin and/or levoﬂoxacin were
susceptible to daptomycin. CoNS (MIC90, 0.5mg/L) and
BHS (MIC 90, 0.25mg/L) were also very susceptible to
daptomycin.
Conclusions: Daptomycin displayed signiﬁcant potency
and a wide spectrum of activity against problematic clin-
ical isolates of Gram-positive cocci causing nosocomial
infections in European hospitals, including MDR subsets.
Daptomycin activity remained stable over the 5 year period
evaluated and resistance to other antimicrobial classes did
not adversely affect the high daptomycin activity.
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Background: We determined the in vitro antimicrobial
susceptibilities of Bacillus anthracis isolated in Korea in
order to expand the choices for effective antimicrobial
treatment.
Methods: Sixteen antimicrobials were tested against
92 isolates of the Bacillus cereus group including 69 B.
anthracis, 20 B. cereus and 3 B. mycoides to determine their
MICs, MIC ranges, MIC50s and MIC90s with Etest strips(AB
BIODISK, Solna, Sweden), and broth microdilution method
at 37 ◦C for 24 h.
Results: The results for the 69 B. anthracis isolates
obtained by the broth microdilution method were com-
pared to those generated by the Etest agar gradient
diffusion method. In the Etest agar gradient method, 14.5%
of B. anthracis showed resistance to -lactam antimic-
tobial agents including penicillin (MIC, ≤0.5g/ml) while
91.3% of isolates were intermediate to ceftriaxone (MIC,
>32g/ml) and chloramphenicol (MIC, ≤3 to 4g/ml).
However, in the broth microdilution method, 21.7% of B.
anthracis(MIC, ≤0.5g/ml) showed resistance to penicillin
and intermediate to ceftriaxone (1.4%) and chlorampheni-
col (92.8%). All B. anthracis isolates were susceptible to
amikacin, cephalothin, ciproﬂoxacin, doxycycline, gentam-
icin, kanamycin, rifampicin, streptomycin, tetracycline, and
vancomycin. However, the majority of the B. cereus and
all of the B. mycoides were resistant to the amoxicillin,
ampicillin and penicillin. All B. cereus were susceptible to
amikacin, ciproﬂoxacin, gentamicin, kanamycin and strep-
tomycin.
Conclusion: This study was to examine therapeutic or
prophylactic antimicrobials potentially effective against B.
cereus group isolates using two testing methods.
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Background: Vancomycin is one of the antibiotics
against methicillin-resistant Staphylococcus aureus (MRSA).
Among pharmacokinetic-pharmacodynamic (PK-PD) param-
eters for vancomycin, the ratio of area under the serum
concentration-time curve (AUC) to minimum inhibitory con-
centration (MIC), AUC/MIC, has been considered to be
correlated to efﬁcacy, although Cmin/MIC has been consid-
ered to be correlated to nephrotoxicity. However, there have
been few clinical studies about the relationship of these PK
parameters with clinical efﬁcacy or nephrotoxicity in MRSA
bacteremia.
Methods: From April 2003 to March 2007, all the patients
aged >20 years whose blood cultures were positive for MRSA
at the University of Tokyo Hospital were selected, and the
patients treated with vancomycin alone were enrolled in this
study. A retrospective chart review was performed to col-
lect demographics. AUC/MIC and Cmin/MIC were assumed
by a two-compartment infusion model by VCM-TDM Edition
on Excel Ver.3.0x (provided by Shionogi Co., Osaka, Japan).
Clinical response was deﬁned as resolution of fever, leukocy-
tosis, and reduction of 30% or more of maximum C-reactive
protein on seven days after the onset of bacteremia. Nephro-
toxicity was deﬁned as an increase of 0.5mg/dl or 50% or
more of baseline serum creatine level at the end of van-
comycin treatment. Relationships of AUC/MIC with clinical
response and Cmin/MIC with nephrotoxicity were analyzed.
Results: Average AUC/MIC in good-responders (n = 15)
was not statistically different from that in poor-responders
(n = 16) (384.2± 124.6 vs. 407.6± 172.0, p = 0.66). Average
Cmin/MIC in patients with vancomycin nephrotoxicity was
higher than that in patients without vancomycin nephro-
toxicity, although not statistically different (11.2± 3.1 vs.
9.4± 3.7, p = 0.37).
Conclusion: PK parameters for vancomycin were not cor-
related with clinical efﬁcacy and nephrotoxicity in patients
with MRSA bacteremia. However, further studies are needed
to elucidate the signiﬁcance of the PK parameters, since the
number of the patients enrolled in this study was small.
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